1. The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases
- Author
-
Onne Reerink, Merel S. Koedijk, W. Schillemans, C.J.A. Haasbeek, Heleen M. Ceha, B.J.M. Heijmen, Jeroen Buijsen, Karin Muller, Martijn P.M. Intven, Alejandra Méndez Romero, F. Koppe, Ellen M. Hendriksen, Rob M. van Os, Ines Joye, Pètra M. Braam, Edwin P.M. Jansen, Henrike Westerveld, Radiation Oncology, CCA - Cancer Treatment and quality of life, Radiotherapy, and CCA - Cancer Treatment and Quality of Life
- Subjects
Adult ,Male ,Organs at Risk ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Time Factors ,Stereotactic body radiation therapy ,Colorectal cancer ,Breast Neoplasms ,Kaplan-Meier Estimate ,Radiosurgery ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,0302 clinical medicine ,Breast cancer ,Belgium ,SDG 3 - Good Health and Well-being ,Stomach Neoplasms ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Registries ,Adverse effect ,Lung cancer ,Radiation Injuries ,Aged ,Netherlands ,Aged, 80 and over ,Radiation ,business.industry ,Liver Neoplasms ,Stomach ,Gallbladder ,Middle Aged ,medicine.disease ,Primary tumor ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Toxicity ,Cohort ,Female ,Radiology ,Dose Fractionation, Radiation ,business ,Colorectal Neoplasms ,Follow-Up Studies - Abstract
Contains fulltext : 232797.pdf (Publisher’s version ) (Open Access) PURPOSE: Although various studies have reported that stereotactic body radiation therapy (SBRT) for liver metastases has high local control rates and relatively low toxicity, most series included a small number of patients. We aimed to validate these outcomes in a large multi-institution patient cohort treated in accordance with a common protocol. METHODS AND MATERIALS: A shared web-based registry of patients with liver metastases treated with SBRT was developed by 13 centers (12 in the Netherlands and 1 in Belgium). All the centers had previously agreed on the items to be collected, the fractionation schemes, and the organs-at-risk constraints to be applied. Follow-up was performed at the discretion of the centers. Patient, tumor, and treatment characteristics were entered in the registry. Only liver metastases treated individually as independent targets and with at least 1 radiologic follow-up examination were considered for local control analysis. Toxicity of grade 3 or greater was scored according to the Common Terminology Criteria of Adverse Events (v4.03). RESULTS: Between January 1, 2013, and July 31, 2019, a total of 515 patients were entered in the web-based registry. The median age was 71 years. In total, 668 liver metastases were registered, and 447 were included for local control analysis. The most common primary tumor origin was colorectal cancer (80.3%), followed by lung cancer (8.9%) and breast cancer (4%). The most-used fractionation scheme was 3x18-20 Gy (36.0%), followed by 8x7.5 Gy (31.8%), 5x11-12 Gy (25.5%), and 12x5 Gy (6.7%). The median follow-up time was 1.1 years for local control and 2.3 years for survival. Actuarial 1-year local control was 87%; 1-year overall survival was 84%. Toxicity of grade 3 or greater was found in 3.9% of the patients. CONCLUSIONS: This multi-institutional study confirms the high rates of local control and limited toxicity in a large patient cohort. Stereotactic body radiation therapy should be considered a valuable part of the multidisciplinary approach to treating liver metastases.
- Published
- 2021